Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06066424 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

A Phase 1 study of Solid Tumors, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT06066424: Recruiting Phase 1 study of Solid Tumors, sponsored by M.D. Anderson Cancer Center.

NCT06066424 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 54 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06066424, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine phosphate
  • DRUG Rimiducid
  • DRUG TROP2-CAR-NK Cells

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2023-10-24
Est. Completion 2040-04-30
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT06066424 shows while recruiting

NCT06066424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT06066424 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06066424 about?

NCT06066424 is a clinical study titled "Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)". To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.

What is the current status of trial NCT06066424?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2023-10-24. Estimated completion is 2040-04-30.

What conditions does trial NCT06066424 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06066424?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine phosphate (DRUG), Rimiducid (DRUG), TROP2-CAR-NK Cells (DRUG).

Who is sponsoring clinical trial NCT06066424?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06066424 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06066424's enrollment target sits among peer trials

54 79th of 125 higher than 47 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06066424

Source: ClinicalTrials.gov NCT06066424, the US trial registry maintained by the National Library of Medicine. NCT06066424 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.